A large number of patients with osteoporosis are not receiving appropriate treatment, due in part to concerns regarding drug safety. Great progress has been made to address this crisis in therapy in 2017, including highlighting the patients' views, developing new therapies and treatment strategies and addressing these safety concerns.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Kalluru, R. et al. Randomised trial assessing the impact of framing of fracture risk and osteoporosis treatment benefits in patients undergoing bone densitometry. BMJ Open 7, e013703 (2017).
Bone, H. G. et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 5, 513–523 (2017).
Saag, K. G. et al. Romosozumab or alendronate for fracture prevention in women with osteo-porosis. N. Engl. J. Med. 377, 1417–1427 (2017).
Kendler, D. L. et al. Effects of teriparatide and risedronate on new fractures in postmenopausal women with severe osteoporosis (VERO): a multicenter, double-blind, double-dummy, randomized controlled trial. Lancet 10.1016/S0140-6736(17)32137-2 (2017).
Khosla, S. et al. A crisis in the treatment of osteoporosis. J. Bone Miner. Res. 31, 1485–1487 (2016).
Alami, S. et al. Barriers to effective postmenopausal osteoporosis treatment: a qualitative study of patients' and practitioners' views. PLoS ONE 11, e0158365 (2016).
Cummings, S. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756–765 (2009).
Miller, P. D. et al. Effects of abaloparatide versus placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316, 722–733 (2016).
Cosman, F. et al. Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatement with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial. Mayo Clin. Proc. 92, 200–210 (2017).
Cosman, F. et al. Romosozumab treatment in post menopausal women with osteoporosis. N. Engl. J. Med. 375, 1532–1543 (2016).
The authors declare no competing financial interests.
About this article
Cite this article
Roux, C., Briot, K. Addressing the crisis in the treatment of osteoporosis. Nat Rev Rheumatol 14, 67–68 (2018). https://doi.org/10.1038/nrrheum.2017.218
Organic Letters (2020)
Joint Bone Spine (2020)
Journal of Medical Microbiology (2019)
The Spine Journal (2019)
Hexane Fraction of Turbo brunneus Inhibits Intermediates of RANK-RANKL Signaling Pathway and Prevent Ovariectomy Induced Bone Loss
Frontiers in Endocrinology (2019)